Abstract Submission is now CLOSED
Notification of Acceptance – Week beginning 1st February 2021.
Authors will be advised of the Paper Selection Committee’s decision by week beginning Monday 1st February 2021. Please note that all presenters (poster and oral) will be required to pay the full registration fee.
Abstract Themes
Abstracts can be submitted under any of the 6 themes below:
1. Hazard Characterisation of Nanomaterials and Advanced Materials
2. Alternative Methods for Nanomaterial Hazard Testing
3. Release and Exposure to Nanomaterials and Advanced Materials
4. Risk Assessment of Nanomaterials and Advanced Materials, and their Governance
5. Safe(r) by Design (SbD) of Nanomaterials and Advanced Materials
6. Open Topics
To help you decide which theme to submit your abstract under please find further sub-themes for each main theme below. You can also download here to view in a PDF format.
Abstract Content
Please ensure that enough detail is included to allow reviewers to consider the quality and suitability. Vague abstracts will not be considered for oral presentations.
Submission Guidelines
-Abstracts should be in English
-No longer than 300 words (excluding the title)
-In typeface ‘Arial 12’
-Please use colours, symbols and schemes for improved clarity
-If including graphs the minimum size should be 20 cm
It is suggested to divide the contents of each submission into introduction, results and conclusions, with a summary listing the pertinent results and conclusions.
Bursaries
If funding permits a limited number of bursaries will be offered to presenting authors of oral and poster papers. If you would like to be considered please select this box when submitting your abstract.
| Main Themes | Sub-Themes |
|---|---|
| 1.Hazard Characterisation of nanomaterials and advanced materials | Human health hazard characterization, mechanisms and AOPs |
| Environmental hazard characterization and mechanisms | |
| Standardization of hazard testing | |
| Biocorona | |
| Lysosomal disruption | |
| Use of nanobiomaterials in advanced therapeutics and medical devices | |
| 2. Alternative methods for nanomaterial hazard testing | Advanced tissue models for predicting human health effects |
| Environmental hazard assessment models | |
| Grouping and read-across | |
| In silico models | |
| Nanoinformatics | |
| Integrated approaches to testing and assessment | |
| Non-protected whole organism models eg Drosophila, early life stage zebrafish. | |
| 3. Release and exposure to nanomaterials and advanced materials | Release of nanomaterials across the life cycle |
| Human exposure assessment | |
| Environmental fate and exposure assessment | |
| Uptake and toxicokinetics | |
| Dosimetry | |
| 4. Risk assessment of nanomaterials and advanced materials, and their governance | Decision support systems |
| Risk assessment methodologies | |
| Stakeholder engagement | |
| Risk management frameworks | |
| Governance | |
| 5. Safe(r) by design (SbD) of nanomaterials and advanced materials | Approaches to SbD |
| Tools for supporting SbD | |
| Case studies applying SbD of engineered materials | |
| Case study for SbD of nanobiomaterials |